Penn State Expands Natural Product Research: From Cannabis to Ghost Pipe, the Push for Evidence-Based Plant Medicine

Penn State College of Medicine (搜索)搜索该词条 is broadening its scientific investigation into plant-derived therapeutics, as the newly renamed Center for Cannabis and Natural Product Pharmaceutics (搜索)搜索该词条 expands its research mandate beyond cannabinoids to encompass a diverse array of medicinal plants. The center, which originated in 2019 as the Pennsylvania-approved Medical Marijuana Academic and Clinical Research Center, now aims to bring rigorous biomedical evidence to a field where, according to its director, claims often outpace data.

"Just because something is natural or comes from a plant doesn't mean it's safe nor does it mean it's effective," said Kent Vrana, Elliot S. Vesell Professor of Pharmacology at Penn State College of Medicine (搜索)搜索该词条 and director of the center. "For many medicinal plants, we don't know what makes them effective, how they interact with other plant compounds or medications or what the risks are and that can be a big problem."

The Evidence Gap in Natural Products

Vrana, who has spent over four decades studying how chemical substances interact with the body's systems, points to a fundamental tension in the natural products landscape. While public demand for plant-derived health solutions continues to grow — driven by medical conditions for which no "magic pill" exists or where existing medications carry significant side effects — the pharmaceutical industry has limited incentive to investigate these compounds. "You can't patent the plants and generate exclusive revenue from them," Vrana explained. "Moreover, biomedical research is expensive. So, you often have people making claims about natural products without data or evidence that it's going to work."

This evidence gap is precisely what the center seeks to address. Its mission is to characterize plant compounds systematically — understanding how they work, their therapeutic benefits, optimal delivery methods, and potential risks — so that these compounds can be used "in a more thoughtful and evidence-based manner."

Cannabis查看药品详情 Research: Beyond CBD查看药品详情

Cannabis查看药品详情 remains a central focus of the center's work. Researchers are investigating the medical benefits of cannabinoids alongside potential drug-to-drug interactions, acute toxicity, and the risk of cannabis use disorder (搜索)搜索该疾病. Vrana highlighted a clinically significant concern: cannabis can interfere with prescription drug metabolism. He cited known cases where patients taking the blood thinner Coumadin查看药品详情 developed bleeding problems after starting cannabis use, as the plant compounds interfered with how the anticoagulant is broken down, resulting in increased drug concentrations in the body.

While CBD查看药品详情 is the most widely recognized cannabinoid, the center is also studying lesser-known compounds. "There are others like cannabigerol查看药品详情 and cannabichromene查看药品详情 that are promising, particularly for pain," Vrana noted. The research program is exploring how cannabinoids may help with conditions including neuropathic pain (搜索)搜索该疾病 and pain associated with bone fractures.

From Knitbone to Ghost Pipe: Mining Traditional Knowledge

The center's expanded scope draws on both traditional medicinal knowledge and modern analytical chemistry. Vrana pointed to comfrey, historically known as "knitbone" and used in Appalachia for broken bones, sprains, and bruises. The plant contains allantoin查看药品详情, which stimulates tissue regeneration, and rosemarinic acid (搜索)搜索该药品, an anti-inflammatory compound.

In a striking example of interdisciplinary collaboration, Vrana and Wes Raup-Konsavage, assistant professor in Neuroscience and Experimental Therapeutics at Penn State College of Medicine (搜索)搜索该词条, are working with Josh Kellogg, associate professor of veterinary and biomedical sciences at Penn State, to study ghost pipe — a traditional medicinal plant used for pain management by the Cherokee people. "I couldn't even think about studying ghost pipe without Josh," Vrana said. "This plant, extensively used in the past by the Cherokee, only grows in the wild." Kellogg's team harvests the plant, extracts the resident chemicals, and characterizes their structures, while Vrana and Raup-Konsavage's team tests these chemicals for their ability to manage pain.

The Future: Nature as a Laboratory

Vrana is clear-eyed about the role of plant-derived compounds in the therapeutic armamentarium. "Will plant and natural product extracts replace pharmaceuticals? Absolutely not," he stated. "I hope, however, that for some unmet medical needs for which there is no good approach, nature can help us."

The vision extends beyond individual research programs to building sustainable infrastructure. "We've got to develop an infrastructure and ecosystem in which we are free to explore those compounds in a safe and controlled way and to find out if we can augment what we're doing in the pharmaceutical environment," Vrana said. He also stressed the importance of training the next generation of scientists with skills in extracting plant compounds and characterizing their chemistry, noting that the center is exploring developing more training opportunities for students and early-career researchers.

Reflecting on the collaborative nature of modern science, Vrana observed: "When I started as a research technician, there were only two or three authors on my first published papers. Now, we don't publish anything that doesn't have at least half a dozen people. We're collaborating across disciplines — experts in basic sciences, plant biology and clinical medicine. That's because science is a team sport."